{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ustekinumab+SC&page=2", "query": { "intervention": "Ustekinumab SC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ustekinumab+SC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T15:52:53.957Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01009086", "title": "A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ustekinumab 45 mg", "type": "DRUG" }, { "name": "Ustekinumab 90 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 615, "start_date": "2009-12", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-03-03", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 26, "location_summary": "Encinitas, California • La Jolla, California • San Diego, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009086" }, { "nct_id": "NCT03464136", "title": "Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Placebo for Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Placebo for Adalimumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab (6 mg/kg)", "type": "BIOLOGICAL" }, { "name": "Ustekinumab (90 mg)", "type": "BIOLOGICAL" }, { "name": "Adalimumab (40 mg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2018-03-29", "completion_date": "2021-05-21", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 67, "location_summary": "Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Danbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03464136" }, { "nct_id": "NCT04524611", "title": "Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease (CD)" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 527, "start_date": "2020-09-30", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 72, "location_summary": "Chandler, Arizona • Coronado, California • Irvine, California + 62 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04524611" }, { "nct_id": "NCT03782376", "title": "A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ustekinumab approximately 6 mg/kg (IV)", "type": "DRUG" }, { "name": "Placebo (SC)", "type": "DRUG" }, { "name": "Placebo (IV)", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 1", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2018-12-20", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 28, "location_summary": "La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782376" }, { "nct_id": "NCT04816513", "title": "A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 300, "start_date": "2021-04-14", "completion_date": "2022-01-26", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 3, "location_summary": "Tempe, Arizona • Lincoln, Nebraska • Salt Lake City, Utah", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04816513" }, { "nct_id": "NCT02968108", "title": "A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 45, "start_date": "2017-01-18", "completion_date": "2022-03-18", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 9, "location_summary": "Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02968108" }, { "nct_id": "NCT03167437", "title": "An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2017-10-30", "completion_date": "2035-06-30", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03167437" }, { "nct_id": "NCT04232553", "title": "A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Mirikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 996, "start_date": "2020-06-22", "completion_date": "2028-03", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 54, "location_summary": "Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Gilroy", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04232553" }, { "nct_id": "NCT00267969", "title": "A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "ustekinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor Research & Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 766, "start_date": "2005-12", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2013-06-17", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267969" }, { "nct_id": "NCT01708603", "title": "P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque Psoriasis" ], "interventions": [ { "name": "210 mg brodalumab", "type": "DRUG" }, { "name": "140 mg brodalumab", "type": "DRUG" }, { "name": "ustekinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1831, "start_date": "2012-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2020-01-06", "last_synced_at": "2026-09-29T15:52:53.957Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708603" } ] }